PET

Claritas HealthTech Extends Claritas iPET™ capability with iPETcertum™ for Automated Lesion Detection and Quantification of Isotope Uptake in PET Scans

Retrieved on: 
Donnerstag, Mai 16, 2024
PET, SUV, Health, PET-CT, FDA, Software, AI, Tissue, Q4, Medicine, Medical imaging

iPETcertum™ extends the functionality of Claritas iPET™, an SaMD (Software as a Medical Device) for accelerated and reduced isotope scans for PET, PET-CT/MRI.

Key Points: 
  • iPETcertum™ extends the functionality of Claritas iPET™, an SaMD (Software as a Medical Device) for accelerated and reduced isotope scans for PET, PET-CT/MRI.
  • Claritas iPET™ enables reducing scan time and reducing contrast dose, while yielding diagnostic quality images.
  • iPETcertum™, provides the additional capability of automated and accurate detection and quantification of isotope uptake in tissues and organs quantified by SUV, SUVmax, and volume values.
  • The functionality and capability of both software devices will be featured at the SNMMI Annual Meeting in June 2024 in Toronto.

Perspective Therapeutics Provides Recent Business Highlights and Reports Fiscal Q1 2024 Results

Retrieved on: 
Mittwoch, Mai 15, 2024
Molecular imaging, Mayo Clinic, Investment, PRRT, FDA, BMY, IND, EANM, Prostate, Ligand, Research, Antibody, PET, Bangladesh Technical Education Board, Stony Brook University, PSMA, Fortis Healthcare, Therapeutic index, Society, Neoplasm, Small business, CMC, Melanoma, Cohort, ATM, Bristol Myers Squibb, Business, CATX, Food, Disease, Safety, Cancer, Patient, Radiopharmaceutical, Adenocarcinoma, Nivolumab, Diagnosis, SNMMI, Therapy, Prostate cancer, LNTH, Nuclear medicine, Acquisition, NETS, Glomus tumor, MC1R, Pharmaceutical industry

SEATTLE, May 15, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or “the Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today announced first quarter financial results for the period ended March 31, 2024.

Key Points: 
  • SEATTLE, May 15, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or “the Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today announced first quarter financial results for the period ended March 31, 2024.
  • “I am proud of the progress we are making with our clinical-stage proprietary radiopharmaceuticals,” said Thijs Spoor, Perspective Therapeutics' CEO.
  • The Company was informed by the investigator that preliminary data readout is expected in the second half of 2024.
  • Updated results from Cohorts 1 and 2 of the Phase 1/2a study are expected in the second half of 2024.

Green Life Farms Enhances Sustainability Profile with Redesigned Packaging

Retrieved on: 
Mittwoch, Mai 22, 2024
Recycling, Environmental Health, Sustainability, Technology, Agriculture, Agritech, Natural Resources, Food, Beverage, Environment, Retail, Packaging, Food Tech, Manufacturing, PET, Automation, Butter, Multimedia, Marketing

All Green Life Farms packaging is made from 100% PET recyclable plastic which reflects the company's commitment to quality, innovation, and environmental sustainability.

Key Points: 
  • All Green Life Farms packaging is made from 100% PET recyclable plastic which reflects the company's commitment to quality, innovation, and environmental sustainability.
  • By prioritizing sustainable packaging options, Green Life Farms aims to minimize its environmental impact without compromising on its product integrity.
  • (Photo: Business Wire)
    The new design, developed by Green Life Farms' dedicated team of experts, utilizes 40% less plastic while extending produce shelf life.
  • "We're thrilled to introduce our new packaging design," said Sarah Boone, Director of Marketing at Green Life Farms.

CEL-SCI Corporation Reports Second Quarter Fiscal 2024 Financial Results

Retrieved on: 
Donnerstag, Mai 16, 2024
Other Manufacturing, FDA, Clinical Trials, Manufacturing, Biotechnology, Other Health, Health, Pharmaceutical, General Health, PET, Patient, Survival, Food, Rheumatoid arthritis, Corporation, Head, Safety, Infection, Biopsy, Cancer, Research, Frontiers, European, Pharmaceutical industry

CEL-SCI Corporation (NYSE American: CVM) today reported financial results for the quarter ended March 31, 2024, as well as key recent clinical and corporate developments.

Key Points: 
  • CEL-SCI Corporation (NYSE American: CVM) today reported financial results for the quarter ended March 31, 2024, as well as key recent clinical and corporate developments.
  • In January 2024, the European Medicines Agency’s Paediatric Committee granted CEL-SCI a product-specific waiver of strict requirements for commercialization of cancer drugs in the European Union.
  • General and administrative expenses in the six months ended March 31, 2024 were $4.6 million compared to $4.4 million in the six months ended March 31, 2023.
  • CEL-SCI raised gross proceeds of approximately $7.75 million through a public offering of common stock during the second fiscal quarter.

Contineum Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights

Retrieved on: 
Donnerstag, Mai 16, 2024
Biotechnology, Health, Pharmaceutical, Clinical Trials, Health Technology, PET, Lung, Patient, Pharmacokinetics, RRMS, LPA1, Completion, Marketing, Food, J&J, University, Depression, IND, Therapy, Safety, Conference, Inflammation, Growth, Idiopathic pulmonary fibrosis, Research, IPO, Nomination, Davidson College, Microglia, Poster, Security, IPF, Pharmaceutical industry

In January 2024, Contineum nominated and began preclinical studies for CTX-343, a peripherally restricted (unable to cross the blood-brain-barrier) LPA1R antagonist.

Key Points: 
  • In January 2024, Contineum nominated and began preclinical studies for CTX-343, a peripherally restricted (unable to cross the blood-brain-barrier) LPA1R antagonist.
  • In March 2024, Contineum appointed commercial veteran Olivia Ware to its Board of Directors.
  • As of March 31, 2024, Contineum had cash, cash equivalents and marketable securities of $117.9 million, compared to $125.2 million at the end of 2023.
  • Research and development expenses were $7.8 million for the three months ended March 31, 2024, compared to $3.6 million for the three months ended March 31, 2024.

Food and Beverage Manufacturers Can Overcome Condensation Challenges with Inkjet Printing and Laser Marking

Retrieved on: 
Mittwoch, Mai 15, 2024
Technology, Packaging, Retail, Chemicals, Plastics, Manufacturing, Supply Chain Management, Transport, Other Retail, Software, Hardware, Other Manufacturing, Electronic Design Automation, Logistics, Food, Beverage, Well, PET, BOPP, Refrigeration, Food packaging, CIJ, Glass, Pasteurization, Printing, Mutagen, RPET, Laser, UV, LDPE, Volatile organic compound, Carcinogen, Aluminium, Ink, Organic compound, CO2, HDPE, PVC, Temperature, Rest, Plastic, 3D printing

Food and beverage manufacturers face some of the most difficult printing environments of any industry.

Key Points: 
  • Food and beverage manufacturers face some of the most difficult printing environments of any industry.
  • The goal of a selected printing and marking solution is to fully apply the right code to the correct product every time.
  • Many food and beverage companies choose continuous inkjet (CIJ) printers and inks to apply accurate, trackable codes designed to resist condensation and survive across the supply chain.
  • They can also be adapted to meet food and beverage industry requirements for code content, resolution, contrast and adhesion.”
    Videojet understands the unique needs of the food and beverage industries.

Origin Materials, Inc. Reports Operating and Financial Results for First Quarter 2024

Retrieved on: 
Dienstag, Mai 14, 2024
Packaging, Recycling, Chemicals, Plastics, Environment, Manufacturing, Sustainability, PET, Wood, Petroleum, Forest Stewardship Council, RPET, Carbon, Cosmetics, Depreciation, GAAP, ID, Webcast, FSC, Cryptocurrency

Origin Materials, Inc. (“Origin,” “Origin Materials,” or the “Company”) (Nasdaq: ORGN, ORGNW), the world’s leading carbon negative materials company with a mission to enable the world’s transition to sustainable materials, today announced financial results for its first quarter ended March 31, 2024.

Key Points: 
  • Origin Materials, Inc. (“Origin,” “Origin Materials,” or the “Company”) (Nasdaq: ORGN, ORGNW), the world’s leading carbon negative materials company with a mission to enable the world’s transition to sustainable materials, today announced financial results for its first quarter ended March 31, 2024.
  • We aim to bring our first manufacturing system online during the fourth quarter 2024.
  • Last, but certainly not least, this quarter we were pleased to convert sustainable wood residues at Origin 1 into our versatile intermediates.
  • Company management will host a webcast and conference call on May 14, 2024, at 5:00 p.m. Eastern Time, to discuss the Company's financial results.

Alto Neuroscience Reports First Quarter 2024 Financial Results and Recent Business Highlights

Retrieved on: 
Dienstag, Mai 14, 2024
Mental Health, Health, FDA, Other Health, Clinical Trials, Pharmaceutical, Biotechnology, CIAS, PET, Partnership, Patient, PDE4, Human, EEG, MDD, Central nervous system disease, Depression, Overalls, Safety, NMDA, Dopamine, Neuroscience, CNS, DSM-IV codes, Brain, Society, Psychopharmacology, Research, Schizophrenia, Anhedonia, Cognition, Histamine, Pharmaceutical industry

Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO) today reported financial results for the first quarter ended March 31, 2024, and highlighted recent corporate progress.

Key Points: 
  • Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO) today reported financial results for the first quarter ended March 31, 2024, and highlighted recent corporate progress.
  • Alto is currently evaluating ALTO-100 in a 266-patient Phase 2b study in MDD patients characterized by a memory-based cognitive biomarker.
  • Enrollment is ongoing and the Company expects to report topline data in the second half of 2024.
  • Net Loss: The Company incurred a net loss of $13.4 million for the quarter ended March 31, 2024, as compared to $7.3 million for the quarter ended March 31, 2023.

Printed Electronics Market size is set to grow by USD 47.58 bn from 2023-2027, growing demand for flexible display to boost the market growth, Technavio

Retrieved on: 
Dienstag, Mai 14, 2024
PET, Paper, Glass, Metallic, Printing, Polyethylene terephthalate, Ink, Semiconductor, Internet of things, Traction, Substrate, Growth, Research, Metal, Graphene, RFID, Communication, OLED, Electronics

The Inks segment, a crucial component of printed electronics, includes conductive inks such as Silver, Carbon, Metallic, and emerging Graphene ink.

Key Points: 
  • The Inks segment, a crucial component of printed electronics, includes conductive inks such as Silver, Carbon, Metallic, and emerging Graphene ink.
  • The Printed Electronics Market is a dynamic and innovative research arena in the consumer electronics industry.
  • The Printed Electronics Market is experiencing significant growth due to the development of flexible, lightweight, and cost-effective electronic devices.
  • The market is driven by the increasing demand for flexible and wearable electronics, and the growing adoption of printed electronics in various industries such as healthcare, automotive, and consumer electronics.

SK chemicals Targets the North American market with Circular Recycling Technology participating in NPE 2024

Retrieved on: 
Montag, Mai 13, 2024
PET, Business analyst, Car, OCCC, NPE, Recycling, Plastic, Starch, Orange County Convention Center, Cosmetics, Urethane, Attention, Biomass, Exhibition, Multimedia

ORLANDO, Fla. and SEONGNAM, South Korea, May 13, 2024 /PRNewswire/ -- Following Chinaplas last month, SK chemicals plans to expand the global market by introducing technology that leads the circular recycling industry in North America."

Key Points: 
  • ORLANDO, Fla. and SEONGNAM, South Korea, May 13, 2024 /PRNewswire/ -- Following Chinaplas last month, SK chemicals plans to expand the global market by introducing technology that leads the circular recycling industry in North America."
  • SK chemicals (CEO Jae-hyun Ahn) participated in NPE 2024 (NPE 2024: The Plastics Show, hereinafter NPE) held at the Orange County Convention Center (OCCC) in Orlando, Florida, USA from the 6th to the 10th.
  • In line with this trend, SK chemicals introduced a wide range of sustainable materials using circular recycling technology at NPE.
  • Circular recycling is the name given to SK chemicals' unique chemical recycling method.